Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2025

Segment Reporting [Abstract]

Schedule of Company’s Segments Including a Reconciliation to Income Before Taxes

The tables below provide information about the Company’s segments and include a reconciliation to income before taxes:

Fiscal Year Ended December 31, 2025		Fertility Clinic Services				INVOcell Device				Therapeutics				Total
Revenue from external customers		$	6,721,057			$	120,193			$	-			$	6,841,250
Intersegment revenues			-				27,000				-				27,000
Total revenue			6,721,057				147,193				-				6,868,250
Reconciliation of revenue
Elimination of intersegment revenue															(27,000	)
Total consolidated revenue															6,841,250
Less:
Cost of revenue			4,359,547				30,571				-				4,390,118
Sales and marketing			113,417				-				-				113,417
General and administrative			1,297,157				-				1,414,023				2,711,180
Research and development			-				-				393,470				393,470
Impairment loss			1,397,353								14,645,069				16,042,422
Depreciation and amortization			585,897				9,725				-				595,622
Segment profit (loss)			(1,032,314	)			106,897				(16,452,562	)			(17,404,979	)
Reconciliation of net loss
Other income (loss)															(1,068,353	)
Interest expense															(910,644	)
Loss on disposition											(1,534,517	)			(1,534,517	)
Unallocated amounts:
Other corporate expenses															(6,369,612	)
Loss before taxes															(27,288,105	)

Assets			6,811,259				32,240				-

Fiscal Year Ended December 31, 2024		Fertility Clinic Services				INVOcell Device				Therapeutics				Total
Revenue from external customers		$	6,450,431			$	81,569				-			$	6,532,000
Intersegment revenues			-				29,000				-				29,000
Total revenue			6,450,431				110,569				-				6,561,000
Reconciliation of revenue
Elimination of intersegment revenue															(29,000	)
Total consolidated revenue															6,532,000
Less:
Cost of revenue			3,705,510				11,735				-				3,717,245
Sales and marketing			37,459				-				-				37,459
General and administrative			1,269,465				-				1,130,470				2,399,935
Research and development			-				-				388,530				388,530
Depreciation and amortization			849,700				9,725				-				859,425
Segment profit (loss)			588,297				89,109				(1,519,000	)			(870,594	)
Reconciliation of net loss
Other income (loss)															63,105
Interest expense															(1,035,143	)
Unallocated amounts:
Other corporate expenses															(7,254,902	)
Loss before taxes															(9,118,751	)

Assets			11,263,408				41,965				34,991,743